Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 201335 plus peginterferon alfa-2a and ribavirin in treatment-naive genotype 1 chronic hepatitis C
2010-021716-42Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2011
- Modality
- Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of faldaprevir in hepatitis C virus infection (4 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Sustained Virological Response at 12 weeks after planned treatment end. Started Jan 2011; status: completed.
02
Drugs
faldaprevir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2010-021716-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021716-42.